Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion
1.412,23
USD
+4,26 % +57,74
02:00:20 Uhr,
Nasdaq
Kostenlose Aktienchance per SMS
Ausgewählte Trading-Einschätzungen aufs Handy.
Kommentare 2.939
EURLIT,
05.08.2026 16:26 Uhr
0
Bomben zahlen einfach abverkauft - ist ja auch kein Palantir - ekelhaft !
Burgenländerin,
05.08.2026 13:16 Uhr
0
ELI LILLY $LLY Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $23.0B (Est. $20.7B) 🟢; +48% YoY
🔹 Adj. EPS: $8.38 (Est. $6) 🟢; +33% YoY
🔹 Mounjaro: $9.9B; +91% YoY
🔹 Zepbound: $4.9B (Est. $4.6B) 🟢; +44% YoY
🔹 GM: 85.8%; +1.5pts YoY
FY26 Guide:
🔹 EPS: $35.50-$36.50 (Est. $34.20) 🟢
🔹 Revenue: $85B-$87B (Est. $85.45B) 🟡
🔹 Performance Margin: 49.0%-50.5%
🔹 Tax Rate: unchanged
Other Q2 Metrics:
🔹 Operating Income: $9.0B (Est. $7.28B) 🟢; +31% YoY
🔹 Net Income: $7.1B (Est. $5.42B) 🟢; +25% YoY
🔹 Key Products Revenue: $15.7B
🔸 Acquired IPR&D charges: $2.8B; Q2 EPS included a $3.03 charge
Comments:
🔸 “Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance”
🔸 “With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development”
Meistdiskutiert
Aktien